Guía de Práctica Clínica sobre Lupus Eritematoso Sistémico

382 Van der Goes MC, Jacobs JWG, Boers M, Andrews T, Blom-Bakkers M a M, Buttgereit F
et al. Monitoring adverse events of low-dose glucocorticoid therapy: EULAR
recommendations for clinical trials and daily practice. Ann Rheum Dis 2010; 69: 1913–
1919.
383 Schmajuk G, Yazdany J. Drug monitoring in systemic lupus erythematosus: a systematic
review. Semin Arthritis Rheum 2011; 40: 559–575.
384 Boumpas D, Austin H, Vaughn E, Klippel J, Steinberg A, Yarboro C et al. Controlled
trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in
severe lupus nephritis. Lancet 1992; 340: 741–745.
385 Mitwalli AH, Al Wakeel JS, Hurraib S, Aisha A, Al Suwaida A, Alam A et al.
Comparison of high and low dose of cyclophosphamide in lupus nephritis patients: a longterm
randomized controlled trial. Saudi J Kidney Dis Transpl 2011; 22: 935–940.
386 Sabry A, Abo-Zenah H, Medhat T, Sheashaa H, Mahmoud K, El-Huseini A. A
comparative study of two intensified pulse cyclophosphamide remission-inducing regimens
for diffuse proliferative lupus nephritis: an Egyptian experience. Int Urol Nephrol 2009;
41: 153–161.
387 Deng J, Huo D, Wu Q, Yang Z, Liao Y. A Meta-Analysis of Randomized Controlled
Trials Comparing Tacrolimus with Intravenous Cyclophosphamide in the Induction
Treatment for Lupus Nephritis. Tohoku J Exp Med 2012; 227: 281–288.
388 Henderson L, Masson P, Craig J, Roberts M, Flanc R, Strippoli G et al. Induction and
maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized
controlled trials. Am J Kidney Dis 2013; 61: 74–87.
389 Chan T-M, Tse K-C, Tang CS-O, Mok M-Y, Li F-K. Long-term study of mycophenolate
mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus
nephritis. J Am Soc Nephrol 2005; 16: 1076–1084.
390 Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C et al. Induction therapies for class IV
lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil
or intravenous cyclophosphamide. Lupus 2007; 16: 707–712.
391 Isenberg D, Appel GB, Contreras G, Dooley M a, Ginzler EM, Jayne D et al. Influence of
race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology
(Oxford) 2010; 49: 128–40.
392 Zavada J, Pesickova S, Rysava R, Olejarova M, Horák P, Hrncír Z et al. Cyclosporine A
or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study. Lupus 2010;
19: 1281–1289.
393 Austin HA, Illei GG, Braun MJ, Balow JE. Randomized, controlled trial of prednisone,
cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc
Nephrol 2009; 20: 901–911.
394 Arends S, Grootscholten C, Derksen RHWM, Berger SP, de Sévaux RGL, Voskuyl AE et
al. Long-term follow-up of a randomised controlled trial of
464 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS